Новые препараты для лечения ожирения

Е.А. Ушкалова

Кафедра общей и клинической фармакологии РУДН, Москва


  1. Rueda-Clausen CF, Padwal RS, Sharma AM. New pharmacological approaches for obesity management. Nat Rev Endocrinol 2013;9(8):467–78.

  2. Heuer RD, Rosenzweig C, Steltzner A, et al. 366 days: Nature’s 10. Nature 2012;492(7429):335–43.

  3. Shin JH, Gadde KM. Clinical utility of phentermine/topiramate (Qsymia™) combination for the treatment of obesity. Diabetes Metab Syndr Obes 2013;6:131–99.

  4. Morris M, Lane P, Lee K, Parks D. An integrated analysis of liver safety data from orlistat clinical trials. Obes Facts 2012;5(4):485–94.

  5. Cheung BMY, Cheung TT. Safety of Antiobesity Drugs. Ther Adv Drug Safe 2013;4(4):171–81.

  6. Colman E, Golden J, Roberts M, et al. The FDA’s assessment of two drugs for chronic weight management. N Engl J Med 2012;367(17):1577–79.

  7. Kang JG, Park CY. Anti-Obesity Drugs: A Review about Their Effects and Safety. Diabetes Metab J 2012;36(1):13–25.

  8. Nigro SC, Luon D, Baker WL. Lorcaserin: a novel serotonin 2C agonist for the treatment of obesity. Curr Med Res Opin 2013;29(7):839–48.

  9. Arena Pharmaceuticals Press Releases, 2010. http://invest.arenapharm.com/releases.cfm.

  10. O’Neil PM, Smith SR, Weissman NJ, et al. Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study. Obesity (Silver Spring) 2012;20(7):1426–36.

  11. Thomsen WJ, Grottick AJ, Menzaghi F, et al. Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization. J Pharmacol Exp Ther 2008;325(2):577–87.

  12. Weissman NJ, Sanchez M, Koch GG, et al. Echocardiographic assessment of cardiac valvular regurgitation with lorcaserin from analysis of 3 phase 3 clinical trials. Circ Cardiovasc Imaging 2013;6(4):560–67.

  13. Shram MJ, Schoedel KA, Bartlett C, et al. Abuse potential assessment of lorcaserin, a selective and potent agonist at the serotonin2C (5-HT2C) receptor, in healthy male and female recreational polydrug users. Clin Pharmacol Ther 2010;87:S1.

  14. Kang JG, Park CY. Anti-Obesity Drugs: A Review about Their Effects and Safety. Diabetes Metab J 2012;36(1):13–25.

  15. Heal DJ, Gosden J, Smith SL. What is the prognosis for new centrally-acting anti-obesity drugs? Neuropharmacology. 2012;63(1):132–46.

  16. VI-0521 (QNEXA®) ADVISORY COMMITTEE BRIEFING DOCUMENT. NDA 022580 Endocrinologic and Metabolic Drugs Advisory Committee Meeting July 15, 2010 http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM218821.pdf

  17. Hunt S, Russell A, Smithson WH, et al. Topiramate in pregnancy: preliminary experience from the UK Epilepsy and Pregnancy Register. Neurology 2008;71(4):272–76.

  18. Lisa Nainggolan. New Obesity Drug, Belviq, in US Pharmacies Next Week. Medscape. Jun 07, 2013.

  19. Refusal of the marketing authorisation for Qsiva (phentermine / topiramate) EMA/666052/2012. www.ema.europa.eu/docs/en_GB/document_library/.../WC500134085.pdf

  20. Lam DD, Przydzial MJ, Ridley SH, et al. Serotonin 5-HT2C receptor agonist promotes hypophagia via downstream activation of melanocortin 4 receptors. Endocrinology 2008;149:1323–28.

  21. Smith SR, Weissman NJ, Anderson CM, et al. Behavioral Modification and Lorcaserin for Overweight and Obesity Management (BLOOM) Study Group. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med 2010;363:245–56.

  22. Fidler MC, Sanchez M, Raether B, et al.; BLOSSOM Clinical Trial Group. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. J Clin Endocrinol Metab 2011;96:3067–77.

  23. Chan EW, He Y, Chui CS, Wong AY, et al. Efficacy and safety of lorcaserin in obese adults: a meta-analysis of 1-year randomized controlled trials (RCTs) and narrative review on short-term RCTs. Obes Rev 2013;14(5):383–92.

  24. Guy-Grand B, Apfelbaum M, Crepaldi G, et al. International trial of long-term dexfenfluramine in obesity. Lancet 1989;2:1142–45.

  25. Van Gaal LF, Rissanen AM, Scheen AJ, et al. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005;365:1389–97.

  26. Scheen AJ, Finer N, Hollander P, et al. Efficacy and tolerability of rimonabant in overweight or obese patients with Type 2 diabetes: a randomised controlled study. Lancet 2006;368:1660–72.

  27. Pi-Sunyer FX, Aronne LJ, Heshmati HM, et al. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. J Am Med Assoc 2006;295:761–75.

  28. Apfelbaum M, Vague P, Ziegler, O, et al. Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine. Am J Med 1999;106:179–84.

  29. JamesWP, Astrup A, Finer N, et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM study group. Sibutramine trial of obesity reduction and maintenance. Lancet 2000;356:2119–25.

  30. Fleming JW, McClendon KS, Riche DM. New obesity agents: lorcaserin and phentermine/topiramate. Ann Pharmacother 2013;47(7–8):1007–16.

  31. Gallwitz B. Novel Oral Anti-Obesity Agents: New Perspectives with Lorcaserin? Drugs 2013;73:393–95.

  32. Eisai Inc. Belviq (lorcaserin hydrochloride) tablets, for oral use. 2012. http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022529lbl.pdf.

  33. Fiedorowicz JG, Miller DD, Bishop JR, et al. Systematic Review and Meta-analysis of Pharmacological Interventions for Weight Gain from Antipsychotics and Mood Stabilizers. Curr Psychiatry Rev 2012;8(1):25–36.

  34. Antel J, Hebebrand J. Weight-reducing side effects of the antiepileptic agents topiramate and zonisamide. Handb Exp Pharmacol 2012;(209):433–66.

  35. Richard D, Ferland J, Lalonde J, et al. Influence of topiramate in the regulation of energy balance. Nutrition 2000;16(10):961–66.

  36. Van Gaal LF, Broom JI, Enzi G, Toplak H. Efficacy and tolerability of orlistat in the treatment of obesity: a 6-month dose-ranging study. Orlistat dose ranging study group. Eur J Clin Pharmacol 1999;54:125–32.

  37. Déspres JP, Golay A, Sjöström L. Rimonabant. In: Obesity Lipids Study Group (Ed.), Effects of Rimonabant on Metabolic Risk Factors in Overweight Patients with Dyslipidemia. N Engl J Med 2005;353:2121–34.

  38. Smith SM, Meyer M, Trinkley KE. Phentermine/topiramate for the treatment of obesity. Ann Pharmacother 2013;47(3):340–49.

  39. Garvey WT, Ryan DH, Look M, et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr 2012;95(2):297–308.

  40. Berlie HD, Hurren KM. Evaluation of lorcaserin for the treatment of obesity. Expert Opin Drug Metab Toxicol 2013;9(8):1053–59.

Об авторах / Для корреспонденции

Е.А. Ушкалова – д.м.н., проф., кафедра общей и клинической фармакологии РУДН; e-mail: eushk@yandex.ru

Бионика Медиа